Announcements Trials
Browse Landscape

Phase

Phase 2 67Phase 1 39Phase 1/2 30Phase 3 26Phase 2/3 5Phase 4 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 1Brain Neoplasms 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Temozolomide × Clear all
NCT00686725 2017-06-14

Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)

Merck Sharp & Dohme LLC

Phase 4 Completed
99 enrolled 15 charts
CNS

Glioblastoma

NCT02343081 2015-04-02

Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System

Monte Verde SA

Phase 4 Completed
24 enrolled 13 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡